BCMA-Binding Bispecific Molecule Trimerization for T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma, a bone-marrow malignancy, are ineffective due to low expression of BCMA on myeloma cells, limiting the therapeutic efficacy of traditional antibodies and conjugates, as they fail to achieve sufficient density for efficient ADCC/CDC activation.
Innovation Solution
A bispecific molecule comprising a domain that binds B cell maturation antigen (BCMA) using a proliferation-inducing ligand (APRIL) and a T-cell activating domain, which forms trimers to overcome low BCMA expression and induce T-cell activation, utilizing a trimerization mechanism to amplify the T-cell activating signal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional therapeutic antibodies or conjugates are used to target BCMA, then the treatment approach is simple and well-established, but the low density of BCMA expression on myeloma cells prevents sufficient binding density to trigger efficient ADCC/CDC
Solution Approach 1:
The patent combines multiple functional domains into a single bispecific molecule: an anti-BCMA binding domain (scFv) and a T-cell activating domain (CD3-specific scFv or Fc region). This merging allows the molecule to simultaneously bind BCMA on myeloma cells and recruit T cells, overcoming the low BCMA density problem by directly engaging T cells rather than relying solely on high-density BCMA binding for therapeutic effect.
Solution Approach 2:
The bispecific molecule acts as an intermediary that bridges the gap between low-density BCMA expression and sufficient T-cell activation. By incorporating a T-cell activating domain, the molecule mediates T-cell recruitment and activation even when BCMA binding density is low, translating weak antigen binding into strong immunological response through the intermediary T-cell engagement mechanism.
2Ease of manufacture
If a traditional mAb conjugate with toxin or chemotherapeutic is used, then the targeting mechanism is straightforward, but the small differential between targeted and non-specific uptake limits therapeutic window
Solution Approach 1:
The patent replaces the mechanical/toxin-based killing mechanism of traditional conjugates with a biological immune-mediated mechanism. Instead of directly delivering toxins that rely on uptake differentials, the bispecific molecule recruits T cells to perform the killing function, substituting a passive toxin delivery system with an active immune system engagement that provides better selectivity and reduced off-target effects.
3Reliability
If the bispecific molecule uses a T-cell activating domain to overcome low BCMA expression, then therapeutic efficacy is improved, but the molecular structure and mechanism become more complex
Solution Approach 1:
The bispecific molecule is segmented into distinct functional modules: an anti-BCMA scFv domain for target recognition and a T-cell activating domain (either CD3-specific scFv or Fc region) for immune engagement. These segmented domains are connected through linkers or Fc regions, allowing independent optimization of each function while maintaining overall molecular stability and manufacturability.
Solution Approach 2:
The Fc region of the antibody serves multiple functions: it provides structural stability, enables dimerization for enhanced avidity, and can engage Fc receptors on immune cells for additional activation mechanisms. This multi-functionality reduces the need for separate dedicated components, simplifying the overall design while achieving complex therapeutic effects.
Data Source
AI summary
The present invention provides a bi-specific molecule which comprises: (i) a first domain which binds B cell maturation antigen (BCMA) and comprises at least part of a proliferation-inducing ligand (APRIL); and (ii) a second domain capable of activating a T cell. The invention also provides the use of such a molecule in the treatment of plasma-cell mediated diseases, such as multiple myeloma.